Colgate-Palmolive Company (CL)

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, reduced its stake in Colgate-Palmolive Company (CL) by 5.2% in the second quarter, selling 357,560 shares, but still holds 6.47 million shares valued at approximately $593.3 million. Despite this reduction, analysts generally maintain a "Moderate Buy" rating for Colgate-Palmolive, with an average price target of $99.00. The company recently surpassed quarterly EPS expectations and increased its revenue by 4.9% year-over-year, alongside paying a quarterly dividend of $0.53 per share, representing a 2.3% annualized yield.

Quantbot Technologies LP significantly reduced its stake in Colgate-Palmolive Company (CL) by 95.5% in the second quarter, now holding 1,504 shares valued at $138,000. Despite this, analysts maintain a "Moderate Buy" consensus with an average price target of $99, following Colgate-Palmolive's stronger-than-expected Q2 earnings and a 4.9% revenue increase. The company also pays a quarterly dividend of $0.53 per share, yielding 2.3% annually.

Jupiter Topco LLC recently acquired 107,227 shares of Colgate-Palmolive Company (NYSE:CL) worth approximately $9.8 million. This comes as institutional investors and hedge funds own over 80% of the company, while insiders, including the CEO and COO, have sold shares totaling over $16 million. Colgate-Palmolive reported strong quarterly earnings, beating expectations, and analysts maintain a "Moderate Buy" rating for the stock.

Colgate-Palmolive's Q2 earnings call revealed cautious optimism, with solid operating results balanced against macroeconomic and category headwinds. The company reported broad-based organic growth across divisions, margin recovery, and stronger cash generation, but also acknowledged U.S. market softness, inventory destocking, and cost risks. Management raised full-year gross margin guidance and emphasized continued investment in brand, innovation, and AI despite a conservative organic growth outlook.

Alyeska Investment Group L.P. significantly reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 56.6% in the second quarter, selling 1.25 million shares but still retaining 962,780 shares valued at $88.3 million. Despite this sale, institutional investors collectively own 80.41% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $99. The company also reported strong quarterly earnings, exceeding expectations with an EPS of $0.99 and a 4.9% increase in revenue.